Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

Overview[ - collapse ][ - ]

Purpose The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin plus cyclophosphamide in patients with early stage breast cancer. In addition the study will verify predefined biomarkers as well as discover new biomarkers that could identify patients who are more likely to respond to ixabepilone than standard paclitaxel based therapy.
ConditionBreast Cancer
InterventionDrug: Ixabepilone
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Doxorubicin
PhasePhase 2
SponsorBristol-Myers Squibb
Responsible PartyBristol-Myers Squibb
ClinicalTrials.gov IdentifierNCT00455533
First ReceivedApril 2, 2007
Last UpdatedMay 25, 2011
Last verifiedMay 2011

Tracking Information[ + expand ][ + ]

First Received DateApril 2, 2007
Last Updated DateMay 25, 2011
Start DateOctober 2007
Estimated Primary Completion DateDecember 2009
Current Primary Outcome Measures
  • Percentage of Participants Achieving Pathologic Complete Response (pCR) [Time Frame: at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)] [Designated as safety issue: No]The pCR was defined as no histologic evidence of residual invasive adenocarcinoma in the breast and axillary lymph nodes, with or without the presence of ductal carcinoma in situ (DCIS) in the breast.
  • Percentage of Participants Achieving Pathologic Complete Response (pCR) in Biomarker-Defined Populations [Time Frame: pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.] [Designated as safety issue: No]Beta III tubulin positivity determined by cross-validation method.Optimal cutoff: >=46% tumor cells staining at 2+ or 3+ intensity (corresponding Beta III tubulin positivity=39.4%). Pre-specified cutoff of Beta III tubulin positivity: >=50% 2+ or 3+ cells (corresponding prevalence=38.5%). Optimal cutoffs for TACC3 and CAPG positivity determined by cross-validation method: 6.889 and 6.844 [log2 normalized intensity units], respectively (corresponding to prevalence rates of 43.3% and 44.3%).
  • Percentage of Participants Achieving Pathologic Complete Response (pCR) in 20- and 26-Gene Model Subgroups [Time Frame: pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.] [Designated as safety issue: No]For each of the 2 biomarker sets (20-gene or 26-gene), a multi-gene model was built using penalized logistic regression on all pharmacogenomic evaluable subjects for each treatment arm separately. Receiver Operating Characteristic (ROC) plots for separate arm using 5 fold cross validation were generated. ROC for separate arms using cross over were also added. Further analysis on the multiple gene models (as mentioned in the SAP) was planned only based on the initial findings from the 2 ROC plots.
Current Secondary Outcome Measures
  • Percentage of Participants Achieving Clinical Objective Response [Time Frame: after the last dose of either ixabepilone or paclitaxel (at 12 weeks) but before surgery (4-6 weeks after the last dose of 12 weeks of therapy)] [Designated as safety issue: No]Clinical response was defined as the number of participants who achieved modified World Health Organization's tumor response criteria of clinical complete response (complete disappearance of all clinically palpable detectable malignant disease and/or disappearance of radiological evidence of tumor in the breast and ipsilateral axillary lymph nodes) or clinical partial response (clinical evidence of a reduction in total tumor size of >= 50% in the overall sum of the products of diameters of breast and axillary lesions), divided by the number of randomized participants in that arm.
  • Percentage of Participants Requiring Breast Conservation Surgery [Time Frame: at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)] [Designated as safety issue: No]Number of randomized participants requiring breast conservation surgery following study treatment.
  • Percentage of Participants Achieving Combined pCR and Minimal Residual Cancer Burden (RCB) 1 [Time Frame: at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)] [Designated as safety issue: No]Combined pCR and RCB-1 was defined as participants with no histologic evidence of residual invasive adenocarcinoma in the breast and axillary lymph nodes, with or without the presence of DCIS in the breast plus subjects with RCB-1 following the RCB calculation based on data entered by the investigator sites in each arm.
  • Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]), to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR [Time Frame: pCR evaluated at time of surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.] [Designated as safety issue: No]Relevance of biomarker in differentiation between ixabepilone & paclitaxel evaluated by logistic regression with pCR as response. Statistical analyses include: 1) the likelihood ratio test between the full model (PCR~Biomarker:Treatment:estrogen receptor [ER]) & reduced model (PCR~Treatment:ER); 2) the likelihood ratio test between the full model (PCR~Biomarker:Treatment) & reduced model (PCR~Biomarker+Treatment); 3) the contrast of the interaction between treatment & biomarker expression within ER Negative subjects from the full model(PCR~Biomarker:Treatment:ER). A:B represents A,B & A*B.
  • Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1 [Time Frame: pCR evaluated at time of surgery (4-6 weeks after the last dose of therapy); mandatory tumor tissue biopsy obtained prior to treatment.] [Designated as safety issue: No]Relevance of biomarker in differentiation between ixabepilone & paclitaxel evaluated by logistic regression with pCR/RCB1 as response. Statistical analyses include: 1) likelihood ratio test between the full model (pCR/RCB1~Biomarker:Treatment: ER) & reduced model (pCR/RCB1~Treatment:ER); 2) likelihood ratio test between the full model (pCR/RCB1 Biomarker:Treatment) & reduced model (pCR/RCB1~Biomarker+Treatment); 3) contrast of the interaction between treatment & biomarker expression within ER Negative subjects from the full model (pCR/RCB1~Biomarker:Treatment:ER). A:B represents A,B & A*B.
  • Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-Specified Thresholds [Time Frame: : pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.] [Designated as safety issue: No]Percentage of participants with pCR in MDR1 IHC positive and negative groups using 2 pre-specified thresholds,. The first pre-specified threshold for MDR1-positivity (Mem) =Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score.
  • Percentage of Participants With pCR/RCB1 and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds [Time Frame: pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.] [Designated as safety issue: No]Percentage of participants with pCR/RCB1 in MDR1 IHC positive and negative groups using 2 pre-specified thresholds,. The first pre-specified threshold for MDR1-positivity (Mem) =Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score .
  • Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds, Estorgen-Receptor (ER) Negative Participants [Time Frame: pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy obtained prior to treatment.] [Designated as safety issue: No]Percentage of ER negative participants with pCR and MDR1 immunohistochemistry (IHC) positivity using 2 pre-specified thresholds, stratified by biomarker status. The first pre-specified threshold for MDR1-positivity (Mem)=Any membrane staining. The second pre-specified threshold for MDR1-positivity (Mem+Cyto)=Any membrane staining or at least 200 Cytoplasmic H-score.
  • Prevalence of Biomarker Based on Optimal Threshold (Biomarker Positive Participants) [Time Frame: pCR evaluated at time of surgery (4-6 weeks after the last dose of 12 weeks of therapy); mandatory tumor tissue biopsy and mRNA samples obtained prior to treatment] [Designated as safety issue: No]Percentage of participants having the following optimal biomarker thresholds as computed from the cross-validation method (cutoff of biomarker positive [with 90% confidence interval by Bootstrap method]): Beta 3 Tubulin IHC (45.866 [5, 83.9]); TACC3 mRNA (6.714 [6.312, 7.192]); CAPG mRNA (6.739 [5.728, 7.298]). Optimal thresholds for a 20-gene model and a 26-gene model were also planned; however, these were not determined because preliminary analyses did not indicate that they would not differentiate pCR rates between treatment arm.
  • Overall Safety Summary: Deaths, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Drug-Related AEs, and Most Common Treatment-Related Non-Hematologic Adverse Events (TNAEs) Occuring in >=10% of Participants [Time Frame: prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy] [Designated as safety issue: Yes]AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. By Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grades
  • Severity of Any Drug-Related AEs and Gastrointestinal AEs by System Organ Class [Time Frame: prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy] [Designated as safety issue: Yes]MCT=musculoskeletal and connective tissue, GDASC=general disorders and administration site conditions, RTM=respiratory, thoracic and mediastinal disorders, NBMUCP=neoplasms benign, malignant and unspecified (including cysts and polyps). Drug related adverse events are those events with relationship to study therapy of certain, probable, possible or missing. Subjects may have more than one event within a class. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)
  • On-Study Hematology: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase [Time Frame: prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy during ixabepilone or paclitaxel treatment phase] [Designated as safety issue: Yes]AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)
  • On-Study Liver Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase [Time Frame: prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of study therapy during ixabepilone or paclitaxel treatment phase] [Designated as safety issue: Yes]Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST). AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)
  • On-Study Renal Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase [Time Frame: prior to the first study treatment, at the beginning of each subsequent cycle, weekly during the treatment period and a minimum of 4 weeks after the last dose of 12 weeks of study therapy during ixabepilone or paclitaxel treatment phase] [Designated as safety issue: Yes]AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)
  • Number of Participants by Dose for AC [Time Frame: 12 weeks (4 3-week cycles)] [Designated as safety issue: Yes]
  • Number of Participants by Dose for Ixabepilone/Paclitaxel [Time Frame: 12 weeks (4 3-week cycles for ixabepilone and 12 weekly doses for paclitaxel)] [Designated as safety issue: Yes]
  • Reason for First Dose Reduction of AC [Time Frame: 12 weeks (4 3-week cycles)] [Designated as safety issue: Yes]
  • Reason for First Dose Reduction of Ixabepilone/Paclitaxel [Time Frame: 12 weeks (4 3-week cycles for ixabepilone and 12 weekly doses for paclitaxel)] [Designated as safety issue: Yes]
  • Number of Participants With Course Delay and Reason for Delay for AC [Time Frame: 12 weeks (4 3-week cycles)] [Designated as safety issue: Yes]
  • Number of Participants With Dose Delay and Reason for Dose Delay for Ixabepilone/Paclitaxel [Time Frame: 12 weeks (4 3-week cycles for ixabepilone and 12 weekly doses for paclitaxel)] [Designated as safety issue: Yes]

Descriptive Information[ + expand ][ + ]

Brief TitleStudy to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
Official TitleA Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Brief Summary
The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus
cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin
plus cyclophosphamide in patients with early stage breast cancer. In addition the study
will verify predefined biomarkers as well as discover new biomarkers that could identify
patients who are more likely to respond to ixabepilone than standard paclitaxel based
therapy.
Detailed DescriptionNot Provided
Study TypeInterventional
Study PhasePhase 2
Study DesignAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
ConditionBreast Cancer
InterventionDrug: Ixabepilone
Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
Other Names:
  • Epothilone
  • IXEMPRA®
  • BMS-247550
Drug: Paclitaxel
Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
Drug: Cyclophosphamide
Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
Drug: Doxorubicin
Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
Study Arm (s)
  • Experimental: A
  • Active Comparator: B

Recruitment Information[ + expand ][ + ]

Recruitment StatusCompleted
Estimated Enrollment384
Estimated Completion DateDecember 2009
Estimated Primary Completion DateDecember 2009
Eligibility Criteria
Inclusion criteria

- Histologically confirmed primary invasive adenocarcinoma of the breast , T2-3, N0-3,
M0, with tumor size of ≥ 2 cm

- All patients with early stage breast adenocarcinoma may enroll irrespective of
receptor status

- No prior treatment for breast cancer excluding therapy for DCIS

- Karnofsky performance status of 80 - 100

- left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or multiple gated
acquisition (MUGA)

- Adequate hematologic, hepatic and renal function

Exclusion Criteria

- women of child-bearing potential (WOCBP) unwilling or unable to use an acceptable
method to avoid pregnancy during and up to 8 weeks after the last dose of the
investigational drug

- Women who are pregnant or breastfeeding

- Inflammatory or metastatic breast cancer

- Unfit for breast and/or axillary surgery

- Evidence of baseline sensory or motor neuropathy

- Significant history of cardiovascular disease, serious intercurrent illness or
infections including known human immu immunodeficiency virus (HIV) infection

- History of prior anthracycline therapy Allergies to any study medication or
Cremophor® EL
GenderFemale
Ages18 Years
Accepts Healthy VolunteersNo
ContactsNot Provided
Location CountriesUnited States, Argentina, Austria, France, Germany, India, Italy, Korea, Republic of, Peru, Philippines, Russian Federation, Singapore, Spain, Taiwan, United Kingdom

Administrative Information[ + expand ][ + ]

NCT Number NCT00455533
Other Study ID NumbersCA163-100
Has Data Monitoring CommitteeNo
Information Provided ByBristol-Myers Squibb
Study SponsorBristol-Myers Squibb
CollaboratorsNot Provided
Investigators Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Verification DateMay 2011

Locations[ + expand ][ + ]

Comprehensive Cancer Center
Palm Springs, California, United States, 92262
Northwest Oncology & Hematology Associates
Coral Spring, Florida, United States, 33065
Florida Cancer Research Institute
Davie, Florida, United States, 33328
Medical Specialists Of Palm Beaches
Lake Worth, Florida, United States, 33467
Moffitt Cancer Center
Tampa, Florida, United States, 33612
University Medical Center, Inc
Louisville, Kentucky, United States, 40202
University Of New Mexico Cancer Center
Albuquerque, New Mexico, United States, 87131
Albert Einstein Cancer Center
Bronx, New York, United States, 10461
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
Providence Cancer Center
Spokane, Washington, United States, 99204
Local Institution
Capital Federal, Buenos Aires, Argentina, 1425
Local Institution
Capital Federal, Buenos Aires, Argentina, 1417
Local Institution
Buenos Aires, Argentina, 1180AAX
Local Institution
Buenos Aires, Argentina, 1650
Local Institution
Salzburg, Austria, 5020
Local Institution
Vienna, Austria, 1090
Local Institution
Wien, Austria, 1090
Local Institution
Bordeaux, France, 33000
Local Institution
Saint Herblain, France, 44805
Local Institution
Duesseldorf, Germany, 40235
Local Institution
Erlangen, Germany, 91054
Local Institution
Jena, Germany, 07743
Local Institution
New Delhi, Delhi, India, 110 095
Local Institution
Bangalore, Karnataka, India, 560029
Local Institution
Trivandrum, Kerala, India, 695011
Local Institution
Pune, Maharashtra, India, 411001
Local Institution
Bhopal, India, 462001
Local Institution
Hyderabad, India, 500 004
Local Institution
Mumbai, India, 400012
Local Institution
Vellore, India, 632004
Local Institution
Bologna, Italy, 40138
Local Institution
Seoul, Korea, Republic of, 135-710
Local Institution
Seoul, Korea, Republic of, 135-720
Local Institution
Callao, Peru, 2
Local Institution
Lima, Peru, LIMA 11
Local Institution
Lima, Peru, 34
Local Institution
Cebu City, Philippines, 6000
Local Institution
Davao City, Philippines, 8000
Local Institution
Quezon City, Philippines, 1114
Local Institution
Kazan, Russian Federation, 420029
Local Institution
Moscow, Russian Federation, 129128
Local Institution
St Petersburg, Russian Federation, 197022
Local Institution
Singapore, Singapore, 308433
Local Institution
Barcelona, Spain, 08035
Local Institution
Jaen, Spain, 23007
Local Institution
Lleida, Spain, 25198
Local Institution
Taipei, Taiwan, 11217
Local Institution
Taipei, Taiwan, 100
Local Institution
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
Local Institution
Coventry, Warwickshire, United Kingdom, CV22DX